Bevacizumab is a recombinant human monoclonal antibody that binds to vascular endothelial growth factor (VEGF), thereby inhibiting the angiogenesis that occurs during tumour growth. Bevacizumab is used with fluorouracil-based chemotherapy in the treatment of metastatic colorectal cancer
Dosage: 5 mg/kg once every 14 days is given in a solution of 100 mL of sodium chloride 0.9%. The first Dose should be given as an intravenous infusion over 90 minutes.
Vial
13501 EGP
Bevacizumab is a recombinant human monoclonal antibody that binds to vascular endothelial growth factor (VEGF), thereby inhibiting the angiogenesis that occurs during tumour growth. Bevacizumab is used with fluorouracil-based chemotherapy in the treatment of metastatic colorectal cancer
Dosage: 5 mg/kg once every 14 days is given in a solution of 100 mL of sodium chloride 0.9%. The first Dose should be given as an intravenous infusion over 90 minutes.
Note: All the provided information about this drug does not substitute for consulting a doctor.